Peripheral neuropathy associated with ipilimumab: A report of 2 cases

Journal of Immunotherapy

Volumn 38, Issue 2, 2015, Pages 77-79

  Thaipisuttikul, Iyavut ^a   Chapman, Paul ^a   Avila, Edward K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ipilimumab; melanoma; sensorimotor polyneuropathy

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GABAPENTIN; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PACLITAXEL; PREDNISONE; PREGABALIN; TACROLIMUS; TEMOZOLOMIDE; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER IMMUNOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PERONEUS NERVE PARALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; T LYMPHOCYTE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CANCER STAGING; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; LUNG NEOPLASMS; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

AMINES; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; CYCLOHEXANECARBOXYLIC ACIDS; DRUG-INDUCED LIVER INJURY; GAMMA-AMINOBUTYRIC ACID; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MELANOMA; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASM STAGING; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84922738416     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000070     Document Type: Article

References (10)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
3. Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37:485-498.
4. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991-993.
5. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16:589-593.
6. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361: 184-187.
7. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16:2861-2871.
8. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105:14987-14992.
9. Kroner A, Schwab N, Ip CW, et al. The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. Neurobiol Dis. 2009;33:96-103.
10. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24: 321-325.